| 孟庆雨,王述民,许世广.ERCC1、TYMS、RRM1、TUBB3表达与非小细胞肺癌化疗疗效的相关性和意义[J].中国肿瘤,2013,22(8):661-665. |
| ERCC1、TYMS、RRM1、TUBB3表达与非小细胞肺癌化疗疗效的相关性和意义 |
| The Relationship of ERCC1，TYMS，RRM1，TUBB3 Expression with Chemotherapeutic Efficacy in Patients with NSCLC and its Significance |
| 投稿时间：2013-03-08 |
| DOI：10.11735/j.issn.1004-0242.2013.08.A011 |
|
 |
| 中文关键词: 非小细胞肺癌 疗效 ERCC1 TYMS RRM1 TUBB3 化疗 |
| 英文关键词:NSCLC efficacy ERCC1 TYMS RRM1 TUBB3 chemotherapy |
| 基金项目: |
|
| 摘要点击次数: 2600 |
| 全文下载次数: 1313 |
| 中文摘要: |
| 摘 要：［目的］ 探讨非小细胞肺癌(NSCLC)术后标本中ERCC1、TYMS、RRM1、TUBB3表达与化疗疗效的相关性。［方法］ 回顾性分析我院病理确诊的72例NSCLC患者手术切除的肿瘤标本，通过分支DNA-液相芯片法，检测ERCC1、TYMS、RRM1、TUBB3基因mRNA表达水平。［结果］ ERCC1、TYMS、RRM1、TUBB3阳性表达率分别为38.9%（28/72）、62.5%(45/72)、55.6%（46/72）和47.2%（34/72）；4者表达与年龄、性别、吸烟、组织学类型、TNM分期、 淋巴结转移均无关(P>0.05)，TYMS、TUBB3在高、中分化组中的阳性表达率显著低于低分化组 (P=0.003，P<0.001)。ERCC1、TYMS、RRM1和TUBB3阳性表达的化疗患者1年生存率均显著低于阴性表达者（61.5% vs 95.5%，P=0.048；53.5% vs 94.9%，P=0.035；58.6%vs 92.9%，P=0.039；47.8% vs 97.4%，P=0.014）。［结论］ ERCC1、TYMS、RRM1、TUBB3阴性表达者化疗生存率高。ERCC1、TYMS、RRM1、TUBB3阴性表达可作为NSCLC患者临床化疗受益的指标。 |
| 英文摘要: |
| Abstract:［Purpose］ To investigate the relationship of the expression of ERCC1，TYMS，RRM1 and TUBB3 with chemotherapeutic efficacy in patients with NSCLC postoperation.［Methods］ Seventy-two cases with NSCLC pathologically proven were analyzed retrospectively. The mRNA expressions of ERCC1，TYMS，RRM1 and TUBB3 gene were detected by branches DNA-liquid chip method. ［Results］ The positive rate of ERCC1，TYMS，RRM1and TUBB3 was 38.9%(28/72)，62.5%(45/72)，55.6%(40/72) and 47.2%(34/72) respectively.The expression of them were not related to age，gender，smoking，histological type，TNM stage and lymph nodes metastasis(P>0.05). The positive rate of TYMS，TUBB3 in high and moderate differentiation group was lower than those in low differentiation group(P=0.003，P<0.001).The 1-year survival in patients with ERCC1，TYMS，RRM1and TUBB3 positive expression was significantly lesser than that in patients with negative expression (95.5% vs 61.5%，P=0.048；94.9% vs 53.5%，P=0.035；92.9% vs 58.6%，P=0.039；97.4% vs 47.8%，P=0.014).［Conclusions］ The survival is high in NSCLC patients undergoing chemotherapy with ERCC1，TYMS，RRM1and TUBB3 negative expression. The negative expression of ERCC1，TYMS，RRM1 and TUBB3 may be the indicators for patients benefits from chemotherapy. |
|
在线阅读
查看全文 查看/发表评论 下载PDF阅读器 |